Immuneering (NASDAQ:IMRX) Director Purchases $52,725.00 in Stock

Key Points

• Immuneering's Director, Peter Feinberg, recently bought 7,500 shares of the company's stock for approximately $52,725, increasing his total ownership to 149,266 shares.
• The company's stock price declined to $6.67 during trading, with a market cap of $277.06 million and a PE ratio of -3.52.
• Several brokerages have upgraded their price targets for Immuneering, with Oppenheimer raising it to $30.00 and Needham projecting a target of $11.00, reflecting growing analyst confidence.

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Peter Feinberg purchased 7,500 shares of the stock in a transaction on Tuesday, September 30th. The stock was bought at an average cost of $7.03 per share, for a total transaction of $52,725.00. Following the completion of the acquisition, the director owned 149,266 shares in the company, valued at approximately $1,049,339.98. This trade represents a 5.29% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Peter Feinberg also recently made the following trade(s):

• On Monday, September 29th, Peter Feinberg purchased 5,000 shares of Immuneering stock. The stock was bought at an average cost of $7.18 per share, for a total transaction of $35,900.00.

Immuneering Price Performance

Immuneering stock traded down $0.34 during trading hours on Wednesday, hitting $6.67. The company had a trading volume of 1,740,660 shares, compared to its average volume of 1,437,251. The firm has a market cap of $277.06 million, a PE ratio of -3.52 and a beta of 0.43. The firm has a 50-day moving average of $5.54 and a 200 day moving average of $3.29. Immuneering Corporation has a one year low of $1.10 and a one year high of $10.08.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40). As a group, research analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current year.

Hedge Funds Weigh In On Immuneering

Hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP raised its stake in Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock worth $111,000 after buying an additional 10,126 shares during the last quarter. Flower City Capital bought a new stake in Immuneering during the 2nd quarter worth approximately $108,000. HighTower Advisors LLC increased its holdings in Immuneering by 17.7% during the 1st quarter. HighTower Advisors LLC now owns 83,960 shares of the company's stock worth $128,000 after purchasing an additional 12,600 shares in the last quarter. Geode Capital Management LLC grew its position in Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company's stock worth $776,000 after purchasing an additional 4,458 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its position in Immuneering by 57.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company's stock worth $322,000 after purchasing an additional 35,000 shares in the last quarter. Institutional investors own 67.65% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on IMRX. Oppenheimer lifted their price objective on shares of Immuneering from $21.00 to $30.00 and gave the company an "outperform" rating in a research note on Thursday, September 25th. Needham & Company LLC lifted their price objective on shares of Immuneering from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Monday, September 15th. Chardan Capital raised their target price on shares of Immuneering from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Friday, September 26th. Mizuho raised their target price on shares of Immuneering from $8.00 to $10.00 and gave the company an "outperform" rating in a research report on Wednesday, June 18th. Finally, HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of Immuneering in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $16.40.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.